Belgium’s Ablynx has formed its third collaboration with Merck Serono to co-discover and co-develop Nanobody® therapies, this time against two osteoarthritis targets. Ablynx’s Nanobody platform will be utilised to develop multispecific products with extended half-lives. Ablynx will be responsible for all preclinical work on the programmes and, upon acceptance of the preclinical packages by Merck Serono, will have the option to continue on a 50:50 co-development basis and share the resulting profits or pursue a more traditional licensing route.